112 related articles for article (PubMed ID: 20927023)
1. Comparison of efficacy of 2220 MBq versus 3700 MBq I-131 for ablation of thyroid remnant in patients with differentiated thyroid cancer.
Fish SA; Basu S; Alavi A; Mandel SJ
Q J Nucl Med Mol Imaging; 2010 Oct; 54(5):560-3. PubMed ID: 20927023
[TBL] [Abstract][Full Text] [Related]
2. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma.
Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ
Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785
[TBL] [Abstract][Full Text] [Related]
3. Thyroid remnant ablation using 1,110 MBq of I-131 after total thyroidectomy: regulatory considerations on release of patients after unsealed radioiodine therapy.
Kusakabe K; Yokoyama K; Ito K; Shibuya H; Kinuya S; Ito M; Higashi T; Togawa T; Koizumi K; Yoshimura M; Uchiyama M; Okamoto T; Kanaya S; Kanaya K; Yoneyama T; Ikebuchi H; Yanagida S; Shibata K; Segawa K; Yamamoto A
Ann Nucl Med; 2012 May; 26(4):370-8. PubMed ID: 22450825
[TBL] [Abstract][Full Text] [Related]
4. Effects of different doses of radioactive iodine for remnant ablation on successful ablation and on long-term recurrences in patients with differentiated thyroid carcinoma.
Kim EY; Kim TY; Kim WG; Yim JH; Han JM; Ryu JS; Hong SJ; Yoon JH; Gong G; Kim WB; Shong YK
Nucl Med Commun; 2011 Oct; 32(10):954-9. PubMed ID: 21849927
[TBL] [Abstract][Full Text] [Related]
5. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.
Grewal RK; Larson SM; Pentlow CE; Pentlow KS; Gonen M; Qualey R; Natbony L; Tuttle RM
J Nucl Med; 2009 Oct; 50(10):1605-10. PubMed ID: 19759114
[TBL] [Abstract][Full Text] [Related]
6. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
7. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer.
Johansen K; Woodhouse NJ; Odugbesan O
J Nucl Med; 1991 Feb; 32(2):252-4. PubMed ID: 1992028
[TBL] [Abstract][Full Text] [Related]
9. Undetectable thyroglobulin in patients with differentiated thyroid carcinoma and residual radioiodine uptake on a postablation whole-body scan.
Giovanella L; Suriano S; Ceriani L; Verburg FA
Clin Nucl Med; 2011 Feb; 36(2):109-12. PubMed ID: 21220971
[TBL] [Abstract][Full Text] [Related]
10. Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan.
Hommel I; Pieters GF; Rijnders AJ; van Borren MM; de Boer H
Neth J Med; 2016 May; 74(4):152-7. PubMed ID: 27185773
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant thyroid remnant ablation in patients with differentiated thyroid carcinoma confined to the thyroid: a comparison of ablation success with different activities of radioiodine (I-131).
Prpic M; Dabelic N; Stanicic J; Jukic T; Milosevic M; Kusic Z
Ann Nucl Med; 2012 Nov; 26(9):744-51. PubMed ID: 22829399
[TBL] [Abstract][Full Text] [Related]
12. The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I.
Verburg FA; Verkooijen RB; Stokkel MP; van Isselt JW
Nuklearmedizin; 2009; 48(4):138-42; quiz N19-20. PubMed ID: 19384451
[TBL] [Abstract][Full Text] [Related]
13. Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis.
Cheng W; Ma C; Fu H; Li J; Chen S; Wu S; Wang H
J Clin Endocrinol Metab; 2013 Apr; 98(4):1353-60. PubMed ID: 23436920
[TBL] [Abstract][Full Text] [Related]
14. Comparison of treatment efficacy 1 and 2 years after thyroid remnant ablation with 1110 versus 5550 MBq of iodine-131 in patients with intermediate-risk differentiated thyroid cancer.
Aghaei A; Ayati N; Shafiei S; Abbasi B; Zakavi SR
Nucl Med Commun; 2017 Nov; 38(11):927-931. PubMed ID: 28834790
[TBL] [Abstract][Full Text] [Related]
15. 131I Biokinetics and cytogenetic dose estimates in ablation treatment of thyroid carcinoma.
Nascimento AC; Lipsztein JL; Corbo R; Rebelo AM
Health Phys; 2010 Oct; 99(4):457-63. PubMed ID: 20838086
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of lobar ablation versus completion thyroidectomy in differentiated thyroid cancer.
Santra A; Bal S; Mahargan S; Bal C
Nucl Med Commun; 2011 Jan; 32(1):52-8. PubMed ID: 21063234
[TBL] [Abstract][Full Text] [Related]
17. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity.
Rosário PW; Borges MA; Purisch S
J Nucl Med; 2008 Nov; 49(11):1776-82. PubMed ID: 18927337
[TBL] [Abstract][Full Text] [Related]
18. Radioiodine ablation: when and how.
Ambrosetti MC; Colato C; Dardano A; Monzani F; Ferdeghini M
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):473-81. PubMed ID: 19910900
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of persistent radioiodine uptake in the neck shown by diagnostic whole body scan in patients with differentiated thyroid carcinoma after initial surgery and remnant ablation.
Kim EY; Kim WG; Kim WB; Kim TY; Ryu JS; Gong G; Yoon JH; Hong SJ; Lee JH; Baek JH; Shong YK
Clin Endocrinol (Oxf); 2010 Aug; 73(2):257-63. PubMed ID: 20105187
[TBL] [Abstract][Full Text] [Related]
20. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]